LifeMine Therapeutics Inc., a clinical-stage biopharmaceutical company pioneering Top-Down Drug Discovery™, which leverages digital genomic search technology from fungi to source next-generation precision medicines, announced $263 million in financing to accelerate the clinical development of the company's lead program, LIFE-001, and advance its pipeline of novel transplantation and immunology therapies.

LifeMine has completed an oversubscribed $188 million Series E financing led by Milky Way Investments with participation from new investors including Bezos Expeditions, Gates Frontier, and RA Capital Management, alongside continued support from existing investors including GV (Google Ventures), LoLa Capital Partners, GlaxoSmithKline (GSK), Invus and ARCH Venture Partners.

The Series E round builds on the company's previously completed $75 million Series D round with existing investors plus LoLa Capital Partners, bringing total new capital raised to $263 million. Proceeds will support the continued clinical development of LIFE-001, including LifeMine's planned Phase 2 kidney transplant study and Phase 1b islet cell transplant study.